Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas

Clinical trials for Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas explained in plain language.

Never miss a new study

Get alerted when new Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas trials appear

Sign up with your email to follow new studies for Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Promising stomach cancer combo trial pulled before it even started

Disease control Cancelled

This study aimed to see if adding a targeted drug (bemarituzumab) to standard chemotherapy (FLOT) could improve outcomes for people with a certain type of stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The treatment was given before and after surgery. Howe…

Matched conditions: GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAS

Phase 2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC

Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas

Get alerted when new Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas trials appear

Promising stomach cancer combo trial pulled before it even started